Physicians' Academy for Cardiovascular Education

SGLT2 inhibition may improve survival of high risk T2DM patients

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

Literature - Claggett B, Lachin JM, Hantel S et al. - Circulation. 2018;138:1599–1601

Introduction and methods

In patients with type 2 diabetes mellitus (T2DM) and established CVD, empagliflozin, on top of standard of care, reduced the risk of CV death by 38% and all-cause mortality by 32% over a median observation period of 3.1 years [1]. In this actuarial analysis of data from the EMPA-REG OUTCOME trial [1], the long-term benefit of empagliflozin on the residual life span was estimated.

In the EMPA-REG OUTCOME trial, 7,020 patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. For this analysis, complete follow-up data from all treated patients were used to estimate the effect of empagliflozin versus placebo on all-cause mortality over the duration of patients’ lifetimes using patient age as the time scale (rather than time since randomization). Actuarial estimates of the age-specific probabilities of death were produced for the empagliflozin and placebo-treated groups. For patients in each treatment group at each year of age, the expected residual years of survival were estimated as the area under the survival curve. As a consequence of randomization, patient age and treatment do not depend on each other, and therefore the difference in the areas under the survival curve can be interpreted as the effect of treatment on time spent event-free.

Main results

The estimated mean survival by age was:


Applying actuarial methods on EMPA-REG OUTCOME data and assuming that the beneficial effects of empagliflozin remain consistent with long-term use, suggests that the estimated survival of T2DM patients with established CVD improves with empagliflozin versus placebo by 1 to 5 years.


Show references

Find this article online at Circulation

Share this page with your colleagues and friends: